The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle (Q34549725)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle |
scientific article |
Statements
1 reference
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle (English)
1 reference
Wolfgang Hiddemann
1 reference
Christiane Pott
1 reference
Hannes Wandt
1 reference
Martin Dreyling
1 reference
Michael Unterhalt
1 reference
Roswitha Forstpointner
1 reference
Roland Repp
1 reference
Sandra Hermann
1 reference
Annette Hänel
1 reference
Bernd Metzner
1 reference
Frank Hartmann
1 reference
Frank Rothmann
1 reference
Robert Rohrberg
1 reference
Hans-Peter Böck
1 reference
German Low-Grade Lymphoma Study Group
1 reference
29 July 2004
1 reference
1 reference
104
1 reference
10
1 reference
3064-3071
1 reference
Identifiers
1 reference
1 reference